Loading...

IDYA IDEAYA BIOSCIENCES INC Investments/Divestments 8-K Filing

DY B

DY

IDEAYA BIOSCIENCES INC

(IDYA)

2024 8-K

Show Summary

Summary

Financial Results

Management Change

License Agreement

Q3 Financial Results

Clinical Update

Presentation Announcement

Clinical Trial Update

Financial Results Announcement

Agreement with Biocytogen P...

Underwriting Agreement

Financial Update

Clinical Update

Resignation of Officer

Clinical Updates

Annual Meeting of Stockholders

Financial Results Announcement

Agreement with MSD Internat...

Financial Results Announcement

Open Market Sales Agreement

Collaboration Agreement

Lease Agreement

Earnings Reports

Underwriting Agreement

Financial Update

Clinical Updates

Resignation of CFO

Earnings Report

Open Market Sales Agreement

Annual Meeting and Compensa...

Lease Agreement for New Fac...

Amendment to Clinical Trial...

Financial Results Announcement

Underwriting Agreement

Financial Update

Clinical Updates

Financial Results Announcement

External Links:

Ideaya Biosciences, Inc. entered into an Option and License Agreement with Biocytogen Pharmaceuticals for the development and commercialization of a bispecific antibody drug conjugate program, with potential milestone payments of up to $400 million.

AI Assistant

IDEAYA BIOSCIENCES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.